OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics

SUWON, South Korea, May 29, 2018 /PRNewswire/ -- OliX Pharmaceuticals Inc., a leading developer of RNA interference (RNAi) therapeutics (CEO: Dong-ki Lee, Ph.D.), announced that it received the Phase I clinical trial authorization (CTA) with its anti-scar drug, OLX10010, from Medicines...

from PR Newswire: //https://ift.tt/2ITSdix